Three separate story lines converged this week to define where the plaintiff bar sits heading into the final stretch of 2026: a federal circuit court hands the Tylenol-autism MDL a survival ruling, New York leverages its overhauled auto insurance statute to arrest 16 people for staged crashes, and a Camp Lejeune bench ruling shuts down a last-ditch effort to rewrite DOJ's Elective Option calculus. Each development carries practical implications for PI firms across the country.
Second Circuit Locks In the Tylenol MDL Revival
On October 16, the Second Circuit denied Kenvue's petition for panel rehearing and rehearing en banc in the prenatal acetaminophen litigation, leaving intact the court's July ruling that overturned the district court's Daubert-based dismissal. The district court had excluded three plaintiff experts, Drs. Andrea Baccarelli, Brandon Pearson, and Eric Hollander, finding their methodology unreliable. The Second Circuit disagreed in July, and Kenvue's effort to undo that ruling failed last week.
The practical effect: roughly 500 plaintiffs whose claims were dismissed alongside the excluded experts are back in the litigation. The MDL, pending in the Southern District of New York under Judge Denise Cote, can now proceed toward bellwether selection and renewed Daubert proceedings, this time with the circuit court's methodology standards locked in as the controlling framework.
This ruling matters beyond the Tylenol docket. It signals that the Second Circuit is skeptical of broad Daubert exclusions in pharmaceutical mass torts when the underlying science, while contested, draws on peer-reviewed studies the experts can explain and defend. Defense strategies that rely on getting all plaintiff experts thrown out at the gate will face a higher appellate threshold in the circuit going forward. Plaintiff firms with prenatal Tylenol cases in inventory should treat this as a green light to evaluate their case selection against the revived expert standard, not a trigger to file indiscriminately.
The causation question, specifically whether prenatal acetaminophen exposure causes autism spectrum disorder or ADHD at the population level, remains unresolved on the merits. The Second Circuit ruling addresses only the admissibility of the experts who plan to opine on it. A summary judgment round and, eventually, a bellwether trial will provide the next data point on how that underlying science performs before a jury.
New York's Staged Crash Statute Gets Its First Real Test
Governor Hochul's office announced on October 20 that New York state investigators arrested 16 people for staging automobile collisions and submitting fraudulent injury claims to collect nearly $500,000 from insurers. The enforcement action is the first major test of the expanded prosecution authority Hochul pushed through as part of her 2026 auto insurance overhaul, which allows prosecutors to target the organizers of staged-crash networks rather than limiting charges to direct participants in a specific collision.
The New York statute also tightened the definition of a serious injury for insurance purposes, a change that has drawn attention from plaintiff-side auto practitioners who worry about downstream effects on legitimate soft-tissue claims. The fraud enforcement announcement was rolled out alongside data showing year-over-year declines in questionable-claim referrals to the state's fraud bureau, which the governor's office is citing as evidence that the legislative combination is working.
For PI attorneys who handle New York auto cases, the enforcement signal is worth noting on two fronts. First, the expansion of prosecution authority to cover organizers means that clinic owners and attorney-adjacent entities that historically operated in the gray zone of organized fraud now face criminal exposure. Second, the seriousness-of-injury definition changes are almost certainly going to generate litigation over how they apply to real claimants with genuine injuries, and appellate decisions in that space will reshape the pre-litigation demand strategy for New York soft-tissue and sprain-strain cases over the next 12 to 24 months.
The arrested individuals face charges including insurance fraud, grand larceny, and conspiracy. The state has not identified the insurer targets by name, but reports indicate the claims involved a mix of no-fault PIP filings and bodily injury claims. For broader coverage of how auto fraud enforcement affects discovery in legitimate auto accidents practice, the platform's coverage of staged-crash defense tactics is archived in the auto accidents section.
Camp Lejeune Elective Option Math Survives a Challenge
A federal judge in the Eastern District of North Carolina rejected a motion on October 20 from Camp Lejeune claimants who argued that the Department of Justice is calculating settlement offers under the Elective Option program using improperly compressed damages ranges. The claimants contended that DOJ's tier structure undervalues certain disease categories by failing to adequately weight non-economic damages and by applying actuarial discount factors that are more aggressive than comparable mass tort settlements.
The court found that the Elective Option structure, which was established by statute under the Camp Lejeune Justice Act, gives the DOJ administrative discretion over how to configure tier values, and that the plaintiffs had not demonstrated that the formula violates the Act's compensation mandate. The ruling effectively preserves the current offer structure, which has generated more than $968 million in accepted settlements through the end of September 2026.
The decision is a significant setback for the segment of the Camp Lejeune docket that has been holding out for better Elective Option offers or litigation track outcomes. With the statutory deadline for filing new claims having passed on August 10, 2024, the remaining claimants are now locked into whatever disposition path exists: Elective Option acceptance, the expedited litigation track, or protracted discovery. The bench ruling makes the litigation track riskier, because it forecloses the argument that claimants are systematically entitled to more than DOJ is offering.
Uber Sexual Assault MDL: 4,916 Cases and a Third Settlement
The Uber passenger sexual assault MDL entered October with 4,916 pending cases, according to the MDL's October 1 status report. The litigation's third bellwether trial was set to proceed in the Western District of Texas in early October but settled before opening statements. Uber had reached the second consecutive federal bellwether liability finding in April, when a jury found the company liable for a second consecutive time but awarded only $5,000 in damages, a verdict that has complicated plaintiff settlement expectations across the docket.
The pattern of liability findings without significant damages is shaping the negotiating dynamic. Plaintiff firms holding cases that fit the core liability theory, driver background check failures and negligent retention, have a stronger hand than they did a year ago because two separate juries agreed on liability. But the damages anomaly in April's trial has given Uber room to argue that individual case valuations require a trial, not a global resolution. The result is a docket where settlements are happening case by case rather than in bulk.
The MDL's overall inventory reflects a broader slowdown in mass tort growth. According to the judicial panel's October 1 report, the federal MDL docket now carries 204,977 pending actions across 162 active MDLs, the first month in this cycle that both the total case count and the total MDL count have declined simultaneously. The 21 largest MDLs account for more than 193,000 of those cases, meaning the decline is coming from mid-size and smaller dockets closing or being remanded rather than from resolution of the mega-MDLs.
Quick Notes: A Verdict Reversal and a Sentencing That Hit the Plaintiff Bar
A Texas intermediate appellate court reversed a $60 million verdict on October 16, citing a record it described as rife with trial court error. The case involved claims against multiple corporate entities arising from a physical altercation, and the appellate panel found that several entities had been included in the judgment without adequate evidentiary support for their participation in the incident. The reversal is a reminder that plaintiff verdicts in multi-defendant cases require tight, entity-specific liability theories, particularly in Texas, where the proportionate responsibility framework gives defendants room to point at each other when the underlying act is committed by a human employee.
Also on October 20, a federal court sentenced a former New Orleans personal injury attorney to 32 months in prison for orchestrating a scheme to fake collisions with commercial trucks and file fraudulent injury claims. The attorney coordinated with participants who intentionally caused low-speed impacts, then filed lawsuits against carriers and extracted settlements. The sentencing is the latest in a series of prosecutions targeting organized plaintiff-bar fraud and reinforces the exposure that comes with representing clients whose stories do not survive basic verification.
For practitioners tracking how case law and settlements in the Tylenol and Uber MDLs translate into individual case value, and for context on how the MDL case-count data shapes mass tort intake decisions, the platform's product liability and medical malpractice sections have the background. The enforcement stories this week, both the New York staged-crash arrests and the New Orleans sentencing, are a useful reminder that the plaintiff bar's credibility in front of juries and legislators depends on the profession policing the conduct that erodes it.
For ongoing coverage of how these MDL developments affect medical malpractice pharmaceutical cases and the expert-witness standards that govern them, the medical malpractice section covers the Daubert and standard-of-care litigation in detail.